Showing 1571-1580 of 2042 results for "".
- Formycon and Bio Usawa Partner Bio to Provide FYB201/ BioUcenta (Ranibizumab) Across Sub-Saharan Africahttps://modernod.com/news/formycon-and-bio-usawa-partner-bio-to-provide-fyb201-bioucenta-ranibizumab-across-sub-saharan-africa/2482870/Formycon announced a partnership between Bioeq AG—licensee and exclusive global commercialization rights holder for Formycon’s biosimilar FYB201—and African biotechnology company Bio Usawa Biotechnology. The agreement grants Bio Usawa exclusiv
- ForSight Robotics Secures $125 Million in Series B Fundinghttps://modernod.com/news/forsight-robotics-secures-125-million-in-series-b-funding-addressing-global-surgeon-shortage-and-demand-for-ophthalmic-surgery/2482862/ForSight Robotics announced it has completed a $125M Series B round, led by Eclipse. The investment accelerates the next growth phase for the ORYOM Platform, the world’s first robotic surgery platform for cataract and other eye diseases designed to enhance surgical precision, incr
- Valorum Biologics Becomes Commercialization Partner for Formycon’s Eylea Biosimilar FYB203/Ahzantive in the US and Canadahttps://modernod.com/news/valorum-biologics-becomes-commercialization-partner-for-formycons-eylea-biosimilar-fyb203ahzantive-aflibercept-mrbb-in-the-united-states-and-canada/2482861/Formycon announced that Klinge Biopharma, the exclusive owner of the global commercialization rights of FYB203/Ahzantive (aflibercept-mrbb), Formycon’s biosimilar to Eylea, concluded an exclusive license agreement with US biosimilars specialist Valorum Biologics for the comme
- Formycon Receives Approval in the UK for Eylea Biosimilarhttps://modernod.com/news/formycon-receives-approval-in-the-uk-for-eylea-biosimilar/2482680/Formycon and its licensing partner Klinge Biopharma jointly announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved FYB203 (aflibercept), a biosimilar to Eylea (Regeneron), under the brand name Ahzantine. The approval covers the treatment
- Fred Moll, Founder of Intuitive Surgical, Joins ForSight Robotics Board of Directorshttps://modernod.com/news/fred-moll-founder-of-intuitive-surgical-joins-forsight-robotics-board-of-directors/2482664/ForSight Robotics announced that Fred Moll, MD, the founder of Intuitive Surgical, has joined its Board of Directors. Intuitive Surgical is the company behind the da Vinci surgical system, the first robotic surgical platform commercially available in the US 
- Formycon Receives EU Approval for Eylea Biosimilar FYB203 Under the Brand Names Ahzantive and Baiamahttps://modernod.com/news/formycon-receives-eu-approval-for-eylea-biosimilar-fyb203-under-the-brand-names-ahzantive-and-baiama/2482624/Formycon and its licensing partner Klinge Biopharma jointly announce that the European Commission has granted central marketing authorization for FYB203 (aflibercept), a biosimilar to Eylea, under the brand names Ahzantive and Baiama. The app
- Specialty Contact Lens Division WAVE Eye Care Formedhttps://modernod.com/news/specialty-contact-lens-division-wave-eye-care-formed/2482616/EyePrint Prosthetics, Advanced Vision Technologies (AVT), and WAVE Contact Lens System—three providers of specialty contact lens fitting—have united to form WAVE Eye Care, a division dedicated to providing fully customized specialty contact lenses. According to a j
- Science Corporation: PRIMA Clinical Trials Show Restoration of "Form Vision"https://modernod.com/news/science-corporation-announces-breakthrough-in-retinal-implant-technology-prima-clinical-trials-show-restoration-of-form-vision/2482509/Science Corporation, a developer in brain-computer interface (BCI) technology, has announced preliminary results from clinical trials of its PRIMA retina implant. This technology has demonstrated the ability to restore what the company is calling 'form vision' in patients suffer
- Ciliatech to Present 36-Month Follow-Up Results on Intercil Uveal Spacer at Ophthalmology Futures European Forumhttps://modernod.com/news/ciliatech-to-present-36-month-follow-up-results-on-intercil-uveal-spacer-at-ophthalmology-futures-european-forum/2482427/Ciliatech has announced that it will reveal the combined 36-month follow-up results of its SAFARI I & II clinical trials at the Ophthalmology Futures European Forum on September 5. The company will share data on its Intercil Uveal Spacer, a Cilioscleral Interpositioning Device (CID) designed
- Robotic Cataract Surgery Using ForSight Robotics’ Oryom Platform Presented for the First Time at ASCRShttps://modernod.com/news/robotic-cataract-surgery-using-forsight-robotics-oryom-platform-presented-for-the-first-time-at-the-ascrs-annual-meeting/2482229/Robotic cataract surgery using ForSight Robotics’ Oryom platform on a porcine eye was presented at the 2024 ASCRS annual meeting by David F. Chang, MD, marking the debut of this technology at a professional conference. During